Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 4/20 | 0.72 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4657197 | 0.84 | AVPR1A (0.77) | AVPR1AAVPR2POLBKMT2AALDH1A1 | |
| SCHEMBL613242 | 0.84 | AVPR1A (1.00) | AVPR1AAVPR2POLBKMT2AMEN1 | |
| SCHEMBL4359530 | 0.82 | AVPR1A (1.00) | AVPR1AAVPR2POLB | |
| SCHEMBL4659267 | 0.81 | AVPR1A (0.73) | AVPR1AAVPR2POLBKMT2AALDH1A1 | |
| SCHEMBL10265794 | 0.81 | AVPR1A (0.69) | AVPR1AAVPR2POLBKMT2AMEN1 | |
| SCHEMBL4658557 | 0.81 | AVPR1A (0.71) | AVPR1AAVPR2POLBALDH1A1KDM4E | |
| SCHEMBL4358583 | 0.80 | AVPR1A (0.66) | AVPR1AAVPR2POLBHTTKMT2A | |
| SCHEMBL4356064 | 0.80 | AVPR1A (0.71) | AVPR1AAVPR2POLB | |
| SCHEMBL613584 | 0.80 | AVPR1A (0.68) | AVPR1AAVPR2POLBKMT2AALDH1A1 | |
| SCHEMBL4658601 | 0.80 | AVPR1A (0.70) | AVPR1AAVPR2POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931680-B1 | INDOL-3-YL-CARBONYL-AZASPIRO DERIVATIVES AS VASOPRESSIN RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-11-17 | — | — | EP | claimed |
| EP-1931680-A1 | INDOL-3-YL-CARBONYL-AZASPIRO DERIVATIVES AS VASOPRESSIN RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-18 | — | — | EP | claimed |
| WO-2007039438-A1 | INDOL-3-YL-CARBONYL-AZASPIRO DERIVATIVES AS VASOPRESSIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | claimed |
| US-20070072888-A1 | Indol-3-yl-carbonyl-azaspiro derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2007-03-29 | — | — | US | claimed |
| EP-1931680-B1 | INDOL-3-YL-CARBONYL-AZASPIRO DERIVATIVES AS VASOPRESSIN RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-7790752-B2 | Indol-3-yl-carbonyl-azaspiro derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1931680-A1 | INDOL-3-YL-CARBONYL-AZASPIRO DERIVATIVES AS VASOPRESSIN RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039438-A1 | INDOL-3-YL-CARBONYL-AZASPIRO DERIVATIVES AS VASOPRESSIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072888-A1 | Indol-3-yl-carbonyl-azaspiro derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072888-A1 | Indol-3-yl-carbonyl-azaspiro derivatives | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885AVPR2 2/4885POLB 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.